Saxenda vs Wegovy: Daily vs Weekly, and Which Wins in 2026
Key takeaways
- Saxenda (daily liraglutide) averages 5 to 8 percent loss; Wegovy ~15 percent.
- Generic liraglutide made Saxenda's lane the budget option.
- Coverage quirks and individual tolerance keep it clinically relevant.
- Weekly dosing wins adherence; daily dosing offers finer control.
- Same side-effect family: nausea-first, front-loaded, manageable.
Saxenda walked so Wegovy could run: same hormone family, one generation apart. The comparison looks lopsided on paper, yet the older daily pen keeps real-world relevance for reasons the headline numbers miss. Here is the honest 2026 matchup.
The core differences
- Molecules: Saxenda is liraglutide, an earlier GLP-1; Wegovy is semaglutide, engineered for a longer half-life and stronger receptor action.
- Dosing: Saxenda is a daily injection climbing to 3 mg; Wegovy is weekly (or, since 2026, a daily tablet).
- Results: trials put Saxenda around 5 to 8 percent average loss at 56 weeks versus roughly 15 percent for Wegovy: not a subtle gap.
Why Saxenda still gets prescribed
The veteran survives on practicalities:
- Generics arrived: liraglutide's patent expiry brought cheaper generic versions: often the decisive argument where GLP-1 budgets are tight.
- Coverage quirks: some plans and countries cover liraglutide where semaglutide is excluded or waitlisted.
- Adolescent and specific-population approvals: its dossier fits some cases neatly.
- Tolerability preferences: a minority of stomachs simply do better on it, and daily dosing offers finer personal control some users like.
Head-to-head practicalities
Side effects are the same family reunion, nausea first, front-loaded, with Saxenda's daily rhythm spreading them thinner while demanding daily commitment: 365 injections a year versus 52. Adherence data predictably favours weekly dosing; wallets increasingly favour generic daily liraglutide. Effectiveness favours Wegovy decisively at averages, with individual overlap at the margins.
The takeaway
Wegovy wins the results contest by a wide, trial-documented margin; Saxenda wins specific battles on price (generics), coverage and individual fit. In 2026 the older pen is less a competitor than a budget lane and a fallback, and knowing that going in makes the prescriber conversation efficient.
Frequently asked questions
Is Saxenda as good as Wegovy?
On average results, no: trials show roughly half the weight loss. On price with generics, coverage in some plans, and fit for certain patients, it can still be the right practical answer.
Why would a doctor choose Saxenda in 2026?
Cost (generic liraglutide), insurance coverage, specific approvals, patient preference for daily control, or prior good response: practical medicine over podium rankings.
Can I switch from Saxenda to Wegovy?
Yes, it is a common upgrade path, managed by your prescriber with an appropriate semaglutide starting dose rather than a straight swap.
Read next
- Generic Liraglutide: The Budget GLP-1
The cheapest legitimate entry to the class.
- Saxenda Results: Honest Expectations
What 5 to 8 percent looks like in real life.
- Wegovy Results Timeline
The comparison benchmark, mapped.
This article is for general informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your individual situation, and never start or stop a medication without your doctor. See our Medical Disclaimer.